A randomized phase II study of gemcitabine and S-1 combination therapy versus gemcitabine monotherapy for advanced biliary tract cancer
- 26 January 2013
- journal article
- research article
- Published by Springer Science and Business Media LLC in Cancer Chemotherapy and Pharmacology
- Vol. 71 (4), 973-979
- https://doi.org/10.1007/s00280-013-2090-4
Abstract
In order to confirm the impact of adding S-1 to gemcitabine, we conducted a randomized phase II study to compare the combination therapy of gemcitabine plus S-1 to gemcitabine monotherapy in patients with advanced biliary tract cancer. Sixty-two patients with advanced cholangiocarcinoma or gallbladder cancer were randomized to either the combination therapy of gemcitabine and S-1 (gemcitabine 1,000 mg/m2 on days 1 and 15 and S-1 40 mg/m2 b.i.d. on days 1–14, repeated every 4 weeks) or gemcitabine monotherapy (gemcitabine 1,000 mg/m2 on days 1, 8, and 15, repeated every 4 weeks). The primary endpoint of this study was response rate, and the regimen which showed the better response rate was selected as a candidate of phase III study. Tumor response was assessed every two cycles using Response Evaluation Criteria in Solid Tumors criteria version 1.0. The response rates of the combination therapy and the monotherapy were 20.0 and 9.4 %, respectively. The median time-to-progressions and overall survivals of these two treatments were nearly the same (5.6 vs. 4.3 months; 8.9 vs. 9.2 months). Adverse events occurred more frequently in the combination arm. The combination therapy of gemcitabine and S-1 showed the better response rate, but the superiority of this combination therapy was not clear in total. Because the standard of care changed to the combination therapy with gemcitabine and cisplatin during this study, it is difficult to select this combination therapy with a 4-week regimen as a candidate of phase III study.Keywords
This publication has 11 references indexed in Scilit:
- Surgical Resection after Downsizing Chemotherapy for Initially Unresectable Locally Advanced Biliary Tract Cancer: A Retrospective Single-center StudyAnnals of Surgical Oncology, 2012
- Multicenter phase II study of S-1 monotherapy as second-line chemotherapy for advanced biliary tract cancer refractory to gemcitabineInvestigational New Drugs, 2010
- A multi-institution phase II study of gemcitabine/S-1 combination chemotherapy for patients with advanced biliary tract cancerCancer Chemotherapy and Pharmacology, 2010
- Cisplatin plus Gemcitabine versus Gemcitabine for Biliary Tract CancerNew England Journal of Medicine, 2010
- Multicenter, phase II study of gemcitabine and S-1 combination chemotherapy in patients with advanced biliary tract cancerCancer Chemotherapy and Pharmacology, 2009
- Efficacy and Safety of S-1 Monotherapy in Patients with Advanced Biliary Tract AdenocarcinomaOncology, 2009
- S-1 Monotherapy in Patients with Advanced Biliary Tract CancerOncology, 2009
- S-1 monotherapy as first-line treatment in patients with advanced biliary tract cancer: a multicenter phase II studyCancer Chemotherapy and Pharmacology, 2008
- Combining Gemcitabine and Capecitabine in Patients With Advanced Biliary Cancer: A Phase II TrialJournal of Clinical Oncology, 2005
- Phase II study of S-1 in patients with advanced biliary tract cancerBritish Journal of Cancer, 2004